Price (delayed)
$11.78
Market cap
$1.71B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.57
Enterprise value
$1.58B
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing ...
Highlights
Denali Therapeutics's debt has decreased by 19% from the previous quarter and by 6% YoY
The EPS has plunged by 142% YoY but it has increased by 7% from the previous quarter
Denali Therapeutics's equity has increased by 19% YoY but it has decreased by 7% QoQ
The net income has dropped by 191% year-on-year
DNLI's revenue has dropped by 100% year-on-year
Key stats
What are the main financial stats of DNLI
MarketValuationsEarnings
Shares outstanding
145.22M
Market cap
$1.71B
Enterprise value
$1.58B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$487.34M
Net income
-$422.77M
EBIT
-$422.71M
EBITDA
-$413.71M
Free cash flow
-$363.61M
Per shareBalance sheetLiquidity
EPS
-$2.57
EPS diluted
-$2.57
Free cash flow per share
-$2.21
Book value per share
$8.54
Revenue per share
$0
TBVPS
$8.36
Total assets
$1.37B
Total liabilities
$144.5M
Debt
$42.29M
Equity
$1.23B
Working capital
$762.23M
Debt to equity
0.03
Current ratio
8.46
Quick ratio
8.14
Net debt/EBITDA
0.32
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-28.6%
Return on equity
-31.4%
Return on invested capital
-31.6%
Return on capital employed
-33.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNLI stock price
How has the Denali Therapeutics stock price performed over time
Intraday
-7.9%
1 week
-20.3%
1 month
-26.14%
1 year
-37.97%
YTD
-42.2%
QTD
-13.35%
Financial performance
How have Denali Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$487.34M
Net income
-$422.77M
Gross margin
N/A
Net margin
N/A
DNLI financials
The net income has dropped by 191% year-on-year
DNLI's operating income has dropped by 148% year-on-year
DNLI's revenue has dropped by 100% year-on-year
Denali Therapeutics's gross profit has shrunk by 100% YoY
Growth
What is Denali Therapeutics's growth rate over time
DNLI growth chart
Valuation
What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
1.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has plunged by 142% YoY but it has increased by 7% from the previous quarter
Price to book (P/B)
DNLI's price to book (P/B) is 66% less than its 5-year quarterly average of 4.4 and 40% less than its last 4 quarters average of 2.5
Denali Therapeutics's equity has increased by 19% YoY but it has decreased by 7% QoQ
Price to sales (P/S)
DNLI's revenue has dropped by 100% year-on-year
Efficiency
How efficient is Denali Therapeutics business performance
The return on assets has dropped by 151% year-on-year but it has increased by 4.7% since the previous quarter
The return on equity has dropped by 133% year-on-year but it has increased by 4.6% since the previous quarter
The return on invested capital has dropped by 131% year-on-year but it has increased by 3.7% since the previous quarter
Dividends
What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNLI.
Financial health
How did Denali Therapeutics financials performed over time
Assets vs liabilities
The quick ratio has declined by 39% year-on-year and by 15% since the previous quarter
The current ratio has contracted by 38% YoY and by 15% from the previous quarter
Debt vs equity
Denali Therapeutics's debt is 97% less than its equity
DNLI's debt to equity is down by 25% since the previous quarter and by 25% year-on-year
Denali Therapeutics's equity has increased by 19% YoY but it has decreased by 7% QoQ
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.